Small molecule-based immunomodulators for cancer therapy

Immunotherapy has led to a paradigm shift in the treatment of cancer. Current cancer immunotherapies are mostly antibody-based, thus possessing advantages in regard to pharmacodynamics (e.g., specificity and efficacy). However, they have limitations in terms of pharmacokinetics including long half-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yinrong, Yang, Zichao, Cheng, Kui, Bi, Huichang, Chen, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764074/
https://www.ncbi.nlm.nih.gov/pubmed/36562003
http://dx.doi.org/10.1016/j.apsb.2022.11.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764074/
https://www.ncbi.nlm.nih.gov/pubmed/36562003
http://dx.doi.org/10.1016/j.apsb.2022.11.007

Ejemplares similares